1. COVID-19 – the challenge to treat a disease and not a positive RT-PCR test
- Author
-
Danka Obreshkova, Evgenia Kirilova Stankova, Yozlem Ali Kobakova, Stefka Achkova Ivanova, Maria Georgieva Moneva-Sakelarieva, and Petar Atanasov
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.drug_class ,medicine.medical_treatment ,Antibiotics ,Pharmaceutical Science ,Pharmacy ,Disease ,03 medical and health sciences ,Therapeutic approach ,0302 clinical medicine ,Pharmacy and materia medica ,Oxygen therapy ,Internal medicine ,medicine ,diagnostics ,Pharmacology (medical) ,030212 general & internal medicine ,therapy ,Hematology ,business.industry ,SARS-CoV-2 ,Chest-CT ,Test (assessment) ,RS1-441 ,030104 developmental biology ,Real-time polymerase chain reaction ,Chest-X-ray ,business - Abstract
The new pandemic disease COVID is quick spread worldwide.The primary method used for diagnosing of COVID-19 is detecting viral nucleic acids. The main problem with RT-PCR test is the false negative results. The negative RT-PCR does not exclude a SARS-CoV-2 infection and this method should not be used as the only diagnostic criteria. The RT-PCR result does not change the complex treatment of the disease. The aim of the current study is to compare the four groups clinical cases of the different parameters: RT-PCR test, rapid test, clinical picture, laboratory tests as hematology, inflammatory markers, coagulation status and chemistry and imaging examinations: Chest X-ray at and Chest CT scan. Complex therapeutic approach has been implemented: antibiotic, inflammatory, anticoagulants, oxygen therapy, hepatoprotectors, antimycotics, fibrinolytics, probiotics, essential oils, vitamins. During the follow-up period, a tendency for significant reduction and resorption of the pulmonary changes on the CT scans has been seen.
- Published
- 2021